Literature DB >> 20643381

Immune dysfunction in autism: a pathway to treatment.

Milo Careaga1, Judy Van de Water, Paul Ashwood.   

Abstract

Autism is a complex and clinically heterogeneous disorder with a spectrum of symptoms. Clinicians, schools, and service agencies worldwide have reported a dramatic increase in the number of children identified with autism. Despite expanding research, the etiology and underlying biological processes of autism remain poorly understood, and the relative contribution from genetic, epigenetic, and environmental factors remains unclear. Although autism affects primarily brain function (especially affect, social functioning, and cognition), it is unknown to what extent other organs and systems are disrupted. Published findings have identified widespread changes in the immune systems of children with autism, at both systemic and cellular levels. Brain specimens from autism subjects exhibit signs of active, ongoing inflammation, as well as alterations in gene pathways associated with immune signaling and immune function. Moreover, many genetic studies have indicated a link between autism and genes that are relevant to both the nervous system and the immune system. Alterations in these pathways can affect function in both systems. Together, these reports suggest that autism may in fact be a systemic disorder with connections to abnormal immune responses. Such immune system dysfunction may represent novel targets for treatment. A better understanding of the involvement of the immune response in autism, and of how early brain development is altered, may have important therapeutic implications. (c) 2010 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20643381      PMCID: PMC5084232          DOI: 10.1016/j.nurt.2010.05.003

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  128 in total

Review 1.  Receptor tyrosine kinases and the regulation of macrophage activation.

Authors:  P H Correll; A C Morrison; M A Lutz
Journal:  J Leukoc Biol       Date:  2004-01-14       Impact factor: 4.962

2.  Possible association of the extended MHC haplotype B44-SC30-DR4 with autism.

Authors:  R P Warren; V K Singh; P Cole; J D Odell; C B Pingree; W L Warren; C W DeWitt; M McCullough
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Glutamate released by dendritic cells as a novel modulator of T cell activation.

Authors:  Rodrigo Pacheco; Harold Oliva; José M Martinez-Navío; Núria Climent; Francisco Ciruela; José M Gatell; Teresa Gallart; Josefa Mallol; Carmen Lluis; Rafael Franco
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

4.  Seizure disorders in autism.

Authors:  F R Volkmar; D S Nelson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1990-01       Impact factor: 8.829

5.  Increasing knowledge of PTEN germline mutations: Two additional patients with autism and macrocephaly.

Authors:  Gail E Herman; Eric Butter; Benedicta Enrile; Matthew Pastore; Thomas W Prior; Annemarie Sommer
Journal:  Am J Med Genet A       Date:  2007-03-15       Impact factor: 2.802

6.  Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes.

Authors:  Paul Ashwood; Amanda Enstrom; Paula Krakowiak; Irva Hertz-Picciotto; Robin L Hansen; Lisa A Croen; Sally Ozonoff; Isaac N Pessah; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2008-11-15       Impact factor: 3.478

7.  Autism and vitamin D.

Authors:  John Jacob Cannell
Journal:  Med Hypotheses       Date:  2007-10-24       Impact factor: 1.538

8.  The TSC-mTOR signaling pathway regulates the innate inflammatory response.

Authors:  Thomas Weichhart; Giuseppina Costantino; Marko Poglitsch; Margit Rosner; Maximilian Zeyda; Karl M Stuhlmeier; Thomas Kolbe; Thomas M Stulnig; Walter H Hörl; Markus Hengstschläger; Mathias Müller; Marcus D Säemann
Journal:  Immunity       Date:  2008-10-09       Impact factor: 31.745

9.  Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression.

Authors:  C Lintas; R Sacco; K Garbett; K Mirnics; R Militerni; C Bravaccio; P Curatolo; B Manzi; C Schneider; R Melmed; M Elia; T Pascucci; S Puglisi-Allegra; K-L Reichelt; A M Persico
Journal:  Mol Psychiatry       Date:  2008-03-04       Impact factor: 15.992

10.  Neurotoxic autoantibodies mediate congenital cortical impairment of offspring in maternal lupus.

Authors:  Ji Y Lee; Patricio T Huerta; Jie Zhang; Czeslawa Kowal; Eva Bertini; Bruce T Volpe; Betty Diamond
Journal:  Nat Med       Date:  2008-12-14       Impact factor: 53.440

View more
  56 in total

Review 1.  Networking in autism: leveraging genetic, biomarker and model system findings in the search for new treatments.

Authors:  Jeremy Veenstra-VanderWeele; Randy D Blakely
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma.

Authors:  Marjannie Eloi Akintunde; Melissa Rose; Paula Krakowiak; Luke Heuer; Paul Ashwood; Robin Hansen; Irva Hertz-Picciotto; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2015-07-11       Impact factor: 3.478

Review 3.  Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.

Authors:  Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

Review 4.  Modeling autistic features in animals.

Authors:  Paul H Patterson
Journal:  Pediatr Res       Date:  2011-05       Impact factor: 3.756

5.  Anti-brain antibodies are associated with more severe cognitive and behavioral profiles in Italian children with Autism Spectrum Disorder.

Authors:  I S Piras; L Haapanen; V Napolioni; R Sacco; J Van de Water; A M Persico
Journal:  Brain Behav Immun       Date:  2014-01-03       Impact factor: 7.217

Review 6.  The role of immune dysfunction in the pathophysiology of autism.

Authors:  Charity Onore; Milo Careaga; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2011-08-28       Impact factor: 7.217

7.  Psychotropic effects of antimicrobials and immune modulation by psychotropics: implications for neuroimmune disorders.

Authors:  Demian Obregon; Ellisa Carla Parker-Athill; Jun Tan; Tanya Murphy
Journal:  Neuropsychiatry (London)       Date:  2012-08

Review 8.  Consensus paper: pathological role of the cerebellum in autism.

Authors:  S Hossein Fatemi; Kimberly A Aldinger; Paul Ashwood; Margaret L Bauman; Charles D Blaha; Gene J Blatt; Abha Chauhan; Ved Chauhan; Stephen R Dager; Price E Dickson; Annette M Estes; Dan Goldowitz; Detlef H Heck; Thomas L Kemper; Bryan H King; Loren A Martin; Kathleen J Millen; Guy Mittleman; Matthew W Mosconi; Antonio M Persico; John A Sweeney; Sara J Webb; John P Welsh
Journal:  Cerebellum       Date:  2012-09       Impact factor: 3.847

9.  Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development.

Authors:  Paula A Garay; Elaine Y Hsiao; Paul H Patterson; A K McAllister
Journal:  Brain Behav Immun       Date:  2012-07-25       Impact factor: 7.217

10.  Myeloid dendritic cells frequencies are increased in children with autism spectrum disorder and associated with amygdala volume and repetitive behaviors.

Authors:  Elizabeth Breece; Brian Paciotti; Christine Wu Nordahl; Sally Ozonoff; Judy A Van de Water; Sally J Rogers; David Amaral; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2012-10-11       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.